Last edition
News about "bile duct cancer"
FDA Grants Orphan Drug Designation to Zenocutuzumab for Rare Cholangiocarcinoma Subset
Partner Therapeutics secures Orphan Drug Designation for zenocutuzumab-zbco in NRG1 fusion-positive cholangiocarcinoma, strengthening development of targeted therapy for this aggressive rare cancer.
Bile Duct Cancer | 09/02/2026 | By News Bureau | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members